An enduring threat: NPS benzodiazepines in forensic and clinical toxicology from 2021 to 2025
- 24 April 2026
- journal article
- Published by Oxford University Press (OUP) in Journal of Analytical Toxicology
- Vol. 50 (6)
Abstract
The proliferation and sustained detection of novel psychoactive benzodiazepines in forensic and clinical toxicology, combined with their potential for adverse events, poses an enduring threat to public health and safety with complex characteristics and challenges unique from other subclasses of novel psychoactive substances (NPS). This study aimed to systematically review the published effects, observations, and toxicological data from postmortem and human performance studies [including clinical, driving under the influence of drugs (DUID), and drug-facilitated crimes (DFC)] involving NPS benzodiazepines from 2021 to 2025. The challenges this class of compounds presents to clinicians, toxicologists, and medical professionals were also addressed, including both analytical and interpretative challenges. Literature reviews were performed in PubMed, Google Scholar, Google Search, toxicology journals, and conference abstract proceedings using search terms such as “NPS benzodiazepines,” “designer benzodiazepines,” and compound specific searches; authoritative websites such as NPS Discovery, National Forensic Laboratory Information System, and the European Union Drug Agency were also consulted. A total of 259 NPS benzodiazepine-related studies were identified including 29 postmortem, 15 DUID, 27 clinical, and 5 DFC studies detailed in this review. NPS benzodiazepines were widely pervasive in both postmortem and human performance cases with overlapping toxic and recreational concentrations; often involving polysubstance use with other central nervous system depressants and stimulants. Unique clinical presentations, observed effects, and autopsy findings were also reported for NPS benzodiazepines. This review provides an updated, consolidated resource to support toxicologists and clinicians in interpretation, emerging risk assessment, and evolving challenges associated with NPS benzodiazepines across postmortem and human performance settings.Keywords
This publication has 105 references indexed in Scilit:
- Fatal intoxication involving amphetamine, clonazafone, a benzodiazepine prodrug, and fluoro-etonitazene, a new synthetic opioidInternational journal of legal medicine, 2025
- Intoxications involving methoxyacetylfentanyl and U-47700: a study of 3 polydrug fatalitiesInternational journal of legal medicine, 2024
- The alprazolam analogue 4′‐chloro deschloroalprazolam identified in seized capsulesDrug Testing and Analysis, 2022
- Prevalence and concentrations of new designer stimulants, synthetic opioids, benzodiazepines, and hallucinogens in postmortem hair samples: A 13‐year retrospective studyDrug Testing and Analysis, 2021
- What’s in fake “Xanax”? : a dosage survey of designer benzodiazepines in counterfeit pharmaceutical tabletsDrug Testing and Analysis, 2021
- Metonitazene in the United States—Forensic toxicology assessment of a potent new synthetic opioid using liquid chromatography mass spectrometryDrug Testing and Analysis, 2021
- The adulterated XANAX pill: a fatal intoxication with etizolam and caffeineInternational journal of legal medicine, 2020
- The emergence of new psychoactive substance (NPS) benzodiazepines: A reviewDrug Testing and Analysis, 2017
- Human urinary metabolic patterns of the designer benzodiazepines flubromazolam and pyrazolam studied by liquid chromatography–high resolution mass spectrometryDrug Testing and Analysis, 2017
- Characterization of the designer benzodiazepine diclazepam and preliminary data on its metabolism and pharmacokineticsDrug Testing and Analysis, 2014